TriSalus Life Sciences and MD Anderson Announce Strategic Research Collaboration to Evaluate Treatment of Solid Tumors
By: Colorado BioScience Association Date: 04/08/2021
The University of Texas MD Anderson Cancer Center and TriSalus Life Sciences®, an emerging immuno-oncology company committed to transforming outcomes for patients with liver and pancreatic tumors, today announced a strategic research collaboration to evaluate the treatment of tumors of the pancreas and liver by integrating interventional delivery of SD-101, an investigational toll-like receptor 9 (TLR9) agonist, in combination with checkpoint inhibition immunotherapy.
Under the agreement, MD Anderson and TriSalus will collaborate on studies evaluating the administration of investigational SD-101 intravascularly via TriSalus’ Food and Drug Administration (FDA) cleared, proprietary Pressure-Enabled Drug Delivery™ (PEDD™) technology across a range of liver and pancreatic solid tumors. The initial study will focus on liver metastases from uveal melanoma, followed by studies focused on metastatic disease from pancreatic ductal adenocarcinoma and colorectal cancer. Programs for hepatocellular carcinoma and locally advanced pancreatic ductal adenocarcinoma also are under development. TriSalus will provide funding and technology for the studies.
“We’re pleased to collaborate with MD Anderson in pursuit of our collective goal to improve outcomes for patients with tumors of the liver and pancreas. The goal of these studies is to augment the potential of existing therapies through novel drug delivery technology and to investigate the strategic modulation of immune microenvironments with investigational candidate SD-101,” said Steven Katz, M.D., Chief Medical Officer, TriSalus Life Sciences. “Collaborations such as this are an integral part of our development strategy to evaluate treatments to help overcome the challenges inherent to solid tumors and enable a broader population of cancer patients to benefit from immunotherapy.”
Find out more in the press release.